Back to Journals » Journal of Receptor, Ligand and Channel Research » Volume 8

mTOR signaling in the neuropathophysiology of depression: current evidence

Authors Réus G, Quevedo J, Rodrigues AL

Received 17 July 2015

Accepted for publication 30 September 2015

Published 23 November 2015 Volume 2015:8 Pages 65—74

DOI https://doi.org/10.2147/JRLCR.S70351

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Jie Xu

Peer reviewer comments 2

Editor who approved publication: Professor Trevor W. Stone

Gislaine Z Réus,1 João Quevedo,1,2 Ana Lúcia S Rodrigues3

1Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, Santa Catarina, Brazil; 2Center for Translational Psychiatry, Department of Psychiatry and Behavioral Sciences, University of Texas Medical School, Houston, TX, USA; 3Laboratory of Neurobiology of Depression, Department of Biochemistry, Center of Biological Sciences, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil

Abstract: Despite significant progress in major depressive disorder (MDD) research over the past decades, the mechanisms underlying its pathophysiology and treatment remain to be established. The complexity and heterogeneity of MDD involves multiple causes, such as inflammation, genetic, and environmental factors that could be related to poor effectiveness, variability of response to antidepressant drugs, delay in clinical response, and side effects. Ketamine, an N-methyl-D-aspartate receptor antagonist, has been proposed as a revolutionary antidepressant that acts rapidly and is effective for treatment-resistant MDD. Ketamine stimulates mammalian target of rapamycin (mTOR), which is involved in transcription, survival, and cell proliferation. mTOR is an emerging signaling pathway of interest in MDD pathophysiology and treatment. Thus, this review describes the role of mTOR in the pathophysiology of MDD as well as highlights therapeutic targets that modulate mTOR signaling.

Keywords: mTOR, antidepressant, major depressive disorder
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]